Thus, precision diagnosis based on fast genetic testing, which is possible as early as the second trimester of pregnancy, offers a unique opportunity for fetal intervention, which may include targeted treatment with MEK inhibitors before critical/lethal complications such as chylothorax or hydrops occur. Here, MAP2K7 is linked to Chylothorax.